STAT5B and ductal breast carcinoma in situ: To investigate whether previously reported reduced levels of Nuc-pYStat5a/b during breast cancer progression could in part be caused by loss of Stat5a or Stat5b protein expression, a breast tissue progression array (Material I) that included normal breast, ductal carcinoma in situ (DCIS), invasive ductal carcinoma (IDC), and lymph node metastases, was stained for Stat5a or Stat5b with immunofluorescence labeling and quantified with AQUA (Figure 1).